Electromed, Inc. ELMD
Biotechnology: Electromedical & Electrotherapeutic Apparatus · IPO 2011 · data as of November 13, 2026
Electromed, Inc. (ELMD) is a healthcare company listed in the US with a market value of about $199M. In the twelve months to September 30, 2026 it had revenue of $76M and net income of $12M, a net margin of 15.8%.
Its overall Stock Analiz score is 3.6 out of 5 (good). The strongest part is track record (5/5); the weakest is shareholder returns (2/5).
Key numbers: a P/E of 17.6, a price to free cash flow of 22.8, 5-year revenue growth of 16% a year, a 5-year average ROIC of 12%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 6% below the current price.
About Electromed
Electromed is listed in the US and classified in biotechnology: electromedical & electrotherapeutic apparatus, IPO year 2011. Revenue went from $19M in 2015 to $74M in 2026, growth of about 12.9% a year. It was profitable in 10 of the last 10 years in our data. It spends 2% of revenue on research and development.
Score: 3.6 / 5
Checks passed
- P/E below 25
- P/E below the industry median
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
- 5-year EPS growth above 10% a year
- 5-year revenue growth above 8% a year
Checks not passed
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- 3-year free cash flow growth above 10% a year
- Strong R&D investment or growth above 20%
- Pays a dividend
- Share count down over 3 years (buybacks)
- Dividend 3 years in a row
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | TTM | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $76M | $74M | $64M | $55M | $48M | $42M | $36M | $32M | $31M | $28M | $26M |
| Net income | $12M | $11M | $8M | $5M | $3M | $2M | $2M | $4M | $2M | $2M | $2M |
| Free cash flow | $9M | $8M | $11M | $9M | -$333000 | -$2M | $3M | $3M | $1M | $2M | $572358 |
| EPS (diluted) | $1.38 | $1.30 | $0.85 | $0.58 | $0.36 | $0.26 | $0.27 | $0.47 | $0.23 | $0.21 | $0.26 |
| Net margin | 15.8% | 15.3% | 11.8% | 9.4% | 6.6% | 5.5% | 6.6% | 12.8% | 6.3% | 6.5% | 8.6% |
| ROIC | — | 20.2% | 16.3% | 10.8% | 8.2% | 6.7% | 7.2% | 13.4% | 7.4% | 7.7% | 10.8% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
Frequently asked questions
What is Electromed’s P/E ratio?
About 17.6, based on the last twelve months of diluted earnings per share.
Is Electromed stock undervalued?
Our DCF model with moderate assumptions puts its intrinsic value about 6% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.
Does Electromed pay a dividend?
Not currently.
Is Electromed a good stock to buy?
We do not give buy or sell advice. Electromed scores 3.6 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.